Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125,072 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM. Papp KA, et al. Among authors: zhang l. Br J Dermatol. 2018 Mar;178(3):674-681. doi: 10.1111/bjd.16050. Epub 2018 Feb 23. Br J Dermatol. 2018. PMID: 28991370 Clinical Trial.
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P. van de Kerkhof P, et al. Among authors: zhang l. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2. J Eur Acad Dermatol Venereol. 2017. PMID: 27910156 Clinical Trial.
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations.
Blauvelt A, Griffiths CEM, Lebwohl M, Mrowietz U, Puig L, Ball S, Zhang L, Edson-Heredia E, Warner M, Zhu B, Lin CY, Nikaï E, Dey D, Mallbris L, Reich K. Blauvelt A, et al. Among authors: zhang l. Br J Dermatol. 2017 Aug;177(2):587-590. doi: 10.1111/bjd.15463. Epub 2017 Jul 3. Br J Dermatol. 2017. PMID: 28301048 Clinical Trial. No abstract available.
The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C. Reich K, et al. Among authors: zhang l. J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1196-1207. doi: 10.1111/jdv.14252. Epub 2017 May 4. J Eur Acad Dermatol Venereol. 2017. PMID: 28370467 Clinical Trial.
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, Erickson J, Zhang L, Mallbris L, Gerdes S. Gottlieb AB, et al. Among authors: zhang l. J Eur Acad Dermatol Venereol. 2017 Apr;31(4):679-685. doi: 10.1111/jdv.13990. Epub 2016 Nov 2. J Eur Acad Dermatol Venereol. 2017. PMID: 27696577 Free PMC article.
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).
Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P; of the IXORA-P Investigators. Langley RG, et al. Among authors: zhang l. Br J Dermatol. 2018 Jun;178(6):1315-1323. doi: 10.1111/bjd.16426. Epub 2018 May 15. Br J Dermatol. 2018. PMID: 29405255 Clinical Trial.
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C. Bodemer C, et al. Among authors: zhang l. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):938-947. doi: 10.1111/jdv.17002. Epub 2021 Jan 19. J Eur Acad Dermatol Venereol. 2021. PMID: 33068444 Free PMC article. Clinical Trial.
125,072 results
You have reached the last available page of results. Please see the User Guide for more information.